Molecular therapy for pulmonary arterial hypertension: 3-caffeoyl, 4-dihydrocaffeoylquinic acid (CDCQ) inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 15/April/2015, 21.55

Regenerative Stem cell therapy for Myocardial Infarction: Notch-1 improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 15/April/2014, 11.58 am
April 15, 2015
Small molecule-based Life-span extension therapy: Phosphorylated glucosamine inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span via up regulation of its target gene, 15/April/2015, 22.58
April 15, 2015
Show all

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054] by Prof. Thistlethwaite PA, Li X and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for pulmonary arterial hypertension: 3-caffeoyl, 4-dihydrocaffeoylquinic acid (CDCQ) inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3

Significance: This study suggests, for the first time, that 3-caffeoyl, 4-dihydrocaffeoylquinic acid (CDCQ), by increasing the expression of its target gene, it may decrease the expression of Notch3. Thus, pharmacological formulations encompassing 3-caffeoyl, 4-dihydrocaffeoylquinic acid (CDCQ) or its analogues” may be used to treat pulmonary arterial hypertension.

Amount: $ 500*

Undisclosed information: How 3-caffeoyl, 4-dihydrocaffeoylquinic acid (CDCQ) decreases the expression of Notch3 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Molecular therapy for pulmonary arterial hypertension: 3-caffeoyl, 4-dihydrocaffeoylquinic acid (CDCQ) inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 15/April/2015,  21.55,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.